A Long-Term Extension Trial From of SPM 962 in Advanced Parkinson's Disease Patients

Parkinson's Disease Clinical Trial

Official title:

An Open-label Long-term Extension Trial From Phase III of SPM962 (243-08-002) in Advanced Parkinson's Disease Patients With Concomitant Treatment of L-dopa

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01631825
• Other study ID #: 243-08-002
• Status: Completed
• Phase: Phase 3
• First received: June 25, 2012
• Last updated: February 3, 2014
• Start date: October 2009
• Est. completion date: June 2012

Study information

• Verified date: February 2014
• Source: Otsuka Pharmaceutical Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Japan: Ministry of Health, Labor and Welfare
• Study type: Interventional

Clinical Trial Summary

• To investigate the safety of once-daily repeated transdermal administration of SPM 962 within a dose range of 4.5 to 36.0 mg/day (54-week treatment period) in Parkinson's disease (PD) patients treated concomitantly with L-dopa in a multi-center, open-label uncontrolled study.

• To investigate efficacy of SPM 962 in an exploratory manner.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 321
• Est. completion date: June 2012
• Est. primary completion date: June 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Subject completed the preceding trial 243-08-001.

Exclusion Criteria:

• Subject discontinued from the preceding trial 243-08-001.

• Subject had a serious adverse event which association with the investigational drug was not ruled out during trial 243-08-001.

• Subject has a persistent serious adverse event at the baseline, which was observed and association with the investigational drug was ruled out during trial 243-08-001.

• Subject had persistent confusion, hallucination, delusion or excitation during trial 243-08-001.

• Subject has abnormal behavior such as obsessive-compulsive disorder and delusion in 243-08-001 study.

• Subject showed serious or extensive application site reactions beyond the application site in the 243-08-001 study.

• Subject has orthostatic hypotension or a systolic blood pressure (SBP) <= 100 mmHg and has a decrease of SBP from spine to standing position >= 30 mmHg at baseline.

• Subject has a history of epilepsy, convulsion etc. during trial 243-08-001.

• Subject develops serious ECG abnormality at the baseline.

• Subject has QTc-interval >= 500 msec at the baseline or subject has an increase of QTc-interval >= 60 msec from the baseline in the trial 243-08-001 and has a QTc-interval > 470 msec in female or > 450 msec in male at the baseline.

• Subject had a serum potassium level < 3.5 mEq/L at the end of the taper period in trial 243-08-001.

• Subject has a total bilirubin >= 3.0 mg/dL or AST(GOT) or ALT(GPT) greater than 2.5 times of the upper limit of the reference range (or ? 100 IU/L) at the end of the period in trial 243-08-001.

• Subject had BUN >= 30 mg/dL or serum creatinine >= 2.0 mg/dl at the end of the taper period in trial 243-08-001.

• Subject who plans pregnancy during the trial.

• Subject is unable to give consent.

• Subject is judged to be inappropriate for this trial by the investigator for the reasons other than above.

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Parkinson Disease
• Parkinson's Disease

Intervention

Drug:
• SPM 962
SPM 962 transdermal patch once a daily up to 36.0 mg/day

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Otsuka Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence and Severity of Adverse Events (AEs), Vital Signs, and Laboratory Parameters	The safety of the long-term SPM 962 treatment was examined based on the incidence and severity of AEs, vital signs, and laboratory parameters.; AEs of special interest (1-3) are defined as below: sudden onset of sleep; obsessive-compulsive disorder or impulse-control disorder; hallucination, delusion; Application site reaction is scored as -, ±, +, ++, +++, or ++++. More + indicates a greater severity of symptoms. The worst score obtained throughout the evaluation period was to be assessed.	Up to 55 weeks after dosing	Yes
Secondary	Unified Parkinson's Disease Rating Scale (UPDRS) Part 3 Sum Score	Mean change (LOCF) from baseline in UPDRS Part 3 sum score (on state).; UPDRS is a scale for monitoring Parkinson's Disease-related disability and impairment. The UPDRS consists of the following four sub-scales. Part 1: Mentation, Part 2: Activities of Daily Living, Part 3: Motor, Part 4: Complications. Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.	Baseline, Up to 54 weeks after dosing	No
Secondary	UPDRS Part 2 Sum Score (Average of on State and Off State)	Mean change (LOCF) from baseline in UPDRS Part 2 sum score (average of on state and off state).; UPDRS sub-scale Part 2 assesses 13 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.	Baseline, up to 54 weeks after dosing	No
Secondary	Absolute Time Spent "Off"	Mean number of hours in "off state" during a 24-hour period.	Baseline, up to 54 weeks after dosing	No
Secondary	UPDRS Part 1 Sum Score	Mean change (LOCF) from baseline in UPDRS Part 1 sum score.; UPDRS sub-scale Part 1 assesses 4 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.	Baseline, up to 54 weeks after dosing	No
Secondary	UPDRS Part 2 Sum Score (On State)	Mean change (LOCF) from baseline in UPDRS Part 2 sum score (on state). A decrease in the scores means improvement.	Baseline, up to 54 weeks after dosing	No
Secondary	UPDRS Part 2 Sum Score (Off State)	Mean change (LOCF) from baseline in UPDRS Part 2 sum score (off state). A decrease in the scores means improvement.	Baseline, up to 54 weeks after dosing	No
Secondary	UPDRS Part 4 Sum Score	Mean change (LOCF) from baseline in UPDRS Part 4 sum score.; UPDRS sub-scale Part 4 assesses 11 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score.; A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.	Baseline, up to 54 weeks after dosing	No
Secondary	Total of UPDRS Part 1 Sum Score, UPDRS Part 2 Sum Score (Average of on State and Off State), UPDRS Part 3 Sum Score (on State), and UPDRS Part 4 Sum Score	Mean change (LOCF) from baseline in total of UPDRS Part 1 sum score, UPDRS Part 2 sum score (average of on state and off state), UPDRS Part 3 sum score (on state), and UPDRS Part 4 sum score.; A decrease in the scores means improvement.	Baseline, up to 54 weeks after dosing	No
Secondary	The Modified Hoehn & Yahr Severity of Illness	Change (LOCF) from baseline in the Modified Hoehn & Yahr Severity of Illness. The Modified Hoehn & Yahr criteria are measured on the following 8-point scale for staging: 0, No signs of disease; 1, Unilateral disease; 1.5, Unilateral plus axial involvement; 2, Bilateral disease without impairment of balance; 2.5, Mild bilateral disease with recovery on pull test; 3, Mild to moderate bilateral disease, some postural instability, physically independent 4, Severe disability, still able to walk or stand unassisted; and 5, Wheelchair bound or bedridden unless aided.; The data at week 52 is shown.	Baseline, up to 54 weeks after dosing.	No
Secondary	Each Item of UPDRS Part 1	The percentage of subjects with elevated scores for each item of UPDRS Part 1. The data at week 52 is shown.	Baseline, up to 54 weeks after dosing.	No
Secondary	Each Item of UPDRS Part 2 (on State)	The percentage of subjects with elevated scores for each item of UPDRS Part 2 (on state). The data at week 52 is shown.	Baseline, up to 54 weeks after dosing.	No
Secondary	Each Item of UPDRS Part 2 (Off State)	The percentage of subjects with elevated scores for each item of UPDRS Part 2 (off state). The data at week 52 is shown.	Baseline, up to 54 weeks after dosing.	No
Secondary	Each Item of UPDRS Part 2 (Average of on State and Off State)	The percentage of subjects with elevated scores for each item of UPDRS Part 2 (average of on state and off state). The data at week 52 is shown.	Baseline, up to 54 weeks after dosing.	No
Secondary	Total of UPDRS Part 2 Sum Score (Average of on State and Off State) and UPDRS Part 3 Sum Score (on State)	Mean change (LOCF) from baseline in total of UPDRS Part 2 sum score (average of on state and off state) and UPDRS Part 3 sum score (on state).; A decrease in the scores means improvement.	Baseline, up to 54 weeks after dosing	No
Secondary	Each Item of UPDRS Part 3 (on State)	The percentage of subjects with elevated scores for each item of UPDRS Part 3 (on state). The data at week 52 is shown.	Baseline, up to 54 weeks after dosing.	No
Secondary	Each Item of UPDRS Part 4	The percentage of subjects with elevated scores for each item of UPDRS Part 4. The data at week 52 is shown.	Baseline, up to 54 weeks after dosing.	No